Methods. Table S1 . Characteristics of subjects providing the skin samples. 
TO THE EDITOR
Psoriasis is characterized by keratinocyte proliferation, inflammation, and mast cell activation (Schon and Boehncke, 2005) . It is also triggered or exacerbated by acute stress (KatsarouKatsari et al., 1999; Saraceno et al., 2006) ; however, this mechanism remains poorly understood. Stress typically results in release of corticotropinreleasing hormone (CRH) from the hypothalamus and regulates the hypothalamic-pituitary-adrenal (HPA) axis (Chrousos, 1995) through activation of CRH receptor-1 (CRH-R1), leading to immunosuppression. CRH is also found peripherally (Chrousos, 1995) and has pro-inflammatory effects through mast cell activation (Theoharides et al., 1998) . CRH and CRH-R gene expression has been documented in rodent and human skin (Slominski et al., 2001) . In fact, it has been proposed that skin has the equivalent of the HPA axis . In mice, CRH is released from nerve endings (Slominski et al., 2001) , whereas in humans it is synthesized by skin cells , immune cells (Karalis et al., 1997) , and human mast cells (Kempuraj et al., 2004) .
To study the effect of stress and the role of CRH in psoriasis, we investigated, by quantitative PCR, CRH-R expression in affected and unaffected skin of psoriasis patients (n ¼ 13) and skin from normal controls (n ¼ 4), as well as serum CRH levels from psoriasis patients (n ¼ 8) and controls (n ¼ 4). The characteristics of the subjects (Table S1) were as follows: male mean age 47.477.0 years (n ¼ 7); female mean age 28.075.2 years (n ¼ 6); normal subjects (one male, three female subjects, mean age 40715.2 years). All skin biopsies requiring two stitches were collected for diagnostic purposes (Table S1) (a) CRH-R gene expression in skin samples from psoriasis patients (n ¼ 13) and controls (n ¼ 4) by quantitative real-time-PCR was obtained from non-exposed skin (back and gluteal). Samples of unaffected skin of psoriasis patients were obtained from sites at least 15 cm away from lesional areas. All biopsies were immediately placed in RNAlater solution (Ambion Inc., Austin, TX) and stored at À201C. Relative quantities of mRNA expression were normalized using 18S as an internal control. TaqMan was performed with cDNA reverse transcribed from 100 ng RNA from each sample. (b) Serum CRH levels in psoriasis patients (n ¼ 8) and controls (n ¼ 4) measured using an ELISA kit (R&D Systems, Mineapolis, MN) (*Po0.05). Statistics: the efficiency of the quantitative PCR machine was shown to be 1.8 and the equation we use is 1/(1.8^C t ). This value was calculated for each condition and results are expressed as a ratio of mRNA expression for CRH-R to 18S. Results are presented as mean7SD and were compared with controls (set at 1) using one-way analysis of variance on ranks followed by Dunn's correction for multiple comparisons. Significance is denoted by (psor ¼ psoriasis) *Po0.05.
(topical or systemic) for the past month. The PASI score for males was 11.3713.5 and for females was 11.573.7. Expression of CRH-R1 mRNA was lowest in affected samples from psoriasis patients (0.2770.23, n ¼ 13, Po0.05), compared with control patients (Figure  1a) . CRH-R1 expression in unaffected skin from psoriasis patients (0.5370.38) was not statistically different from that of affected samples or controls (Figure 1a) . There was no statistically significant difference in CRH-R2 mRNA expression among the control samples, those obtained from affected (0.8670.51) and from unaffected (0.9770.65) psoriatic skin ( Figure 1a) .
The serum CRH level (11.527 6.09 pg/ml) was higher (n ¼ 8, Po0.05) in psoriasis patients than controls (5.4271.2 pg/ml, n ¼ 8). There was no apparent correlation between the PASI scores and either CRH-R1 expression or serum CRH levels.
This study provides early evidence that affected psoriatic skin has decreased gene expression of CRH-R1 mRNA than normal controls. One possible explanation is that overstimulation by increased levels of local or systemic (serum) CRH in psoriasis patients, possibly in response to chronic stress, may lead to CRH-R1 downregulation. In fact, CRH protein expression was recently reported to be increased in the affected skin of three patients with active psoriasis than in one control; however, this effect was not quantitated (O'Kane et al., 2006) . As non-affected psoriatic skin apparently did not overexpress CRH-R, as shown by our quantitative real-time-PCR data, there was apparently no mechanism in place to lead to downregulation. Increased CRH-R expression in psoriatic skin was also mentioned as ''unpublished observations'' (O'Kane et al., 2006) and it is, therefore, difficult to evaluate it. The reduction in CRH-R1 mRNA expression in affected skin of patients with psoriasis we observed could be due to the intense inflammation seen in plaques without any association with serum CRH levels; however, this possibility is not supported by the literature. In fact, we showed that the inflammation-related molecules IL-1, IL-4, and lipopolysaccharide had no effect on CRH-R1 expression, but increased CRH-R2 expression in human mast cells . CRH-R1 is expressed in keratinocytes and in a subpopulation of skin mast cells (Donelan et al., 2006) . Normal cultured human mast cells also express mRNA and protein for CRH-R1 and CRH-R2 (Cao et al., 2005) . Human skin, squamous cell carcinoma, and melanoma cells also express CRH and CRH-R1 (Slominski et al., , 2001 ). The lack of any significant difference between affected and unaffected or control skin may either indicate (a) that unaffected skin represents an early or intermediate stage, (b) that these areas have different number of cells expressing CRHR, or (c) the variability is too large, given the small number of patients.
Psoriasis is the most common chronic inflammatory skin disorder (Schon and Boehncke, 2005) . It is worsened by stress (Katsarou-Katsari et al., 1999) and is characterized by aberrant HPA function (Richards et al., 2005) ; moreover, neuropeptides appear to induce skin neurogenic inflammation (Saraceno et al., 2006) . The skin may have its own equivalent of the HPA axis and the role of CRH in cutaneous inflammatory diseases was reviewed recently (O'Kane et al., 2006) . Chronic stress and CRH typically attenuate immune processes, whereas acute stress enhances antigen-specific, cell-mediated immunity (Dhabhar and McEwen, 1999) . Stress also exacerbates contact dermatitis in rats (Kaneko et al., 2003) . Acute stress induces local release of CRH in the skin (Lytinas et al., 2003) and increases skin vascular permeability (Singh et al., 1999) , an effect mimicked by intradermal CRH and absent in mast cell-deficient mice (Theoharides et al., 1998) . CRH also increased vascular permeability in human skin, an effect dependent on CRH-R1 and mast cells (Crompton et al., 2003) .
The level of stress in these patients was not quantitated with any validated instrument and it is, therefore, premature to try to make any correlations between our findings and any level of stress in these patients.
Mast cells are involved not only in allergic reactions, but also in innate immunity (Galli et al., 2005) and inflammation (Theoharides and Cochrane, 2004) . Mast cells are juxtaposed to nerve endings during hair follicle formation (Roloff et al., 1998) and are located close to CRHpositive nerve endings (Rozniecki et al., 1999) , suggesting that they are involved in a ''brain-skin'' connection (Paus et al., 2006) , as targets of CRH and related peptides .
The present findings suggest that CRH and CRH-R1 may participate in the pathogenesis of psoriasis, especially when worsened by stress.
